63 related articles for article (PubMed ID: 10975866)
1. Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred.
Mukherjee P; Ginardi AR; Madsen CS; Sterner CJ; Adriance MC; Tevethia MJ; Gendler SJ
J Immunol; 2000 Sep; 165(6):3451-60. PubMed ID: 10975866
[TBL] [Abstract][Full Text] [Related]
2. Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1).
Kohlgraf KG; Gawron AJ; Higashi M; VanLith ML; Shen X; Caffrey TC; Anderson JM; Hollingsworth MA
Cancer Immunol Immunother; 2004 Dec; 53(12):1068-84. PubMed ID: 15696607
[TBL] [Abstract][Full Text] [Related]
3. Mucin-1-related T cell infiltration in colorectal carcinoma.
Mulder WM; Stukart MJ; de Windt E; Wagstaff J; Scheper RJ; Bloemena E
Cancer Immunol Immunother; 1996 Jul; 42(6):351-6. PubMed ID: 8830738
[TBL] [Abstract][Full Text] [Related]
4. In vivo anti-MUC1
Pichinuk E; Chalik M; Benhar I; Ginat-Koton R; Ziv R; Smorodinsky NI; Haran G; Garbar C; Bensussan A; Meeker A; Guillaume T; Rubinstein DB; Wreschner DH
Cancer Immunol Immunother; 2020 Jul; 69(7):1337-1352. PubMed ID: 32219500
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer.
Ramanathan RK; Lee KM; McKolanis J; Hitbold E; Schraut W; Moser AJ; Warnick E; Whiteside T; Osborne J; Kim H; Day R; Troetschel M; Finn OJ
Cancer Immunol Immunother; 2005 Mar; 54(3):254-64. PubMed ID: 15372205
[TBL] [Abstract][Full Text] [Related]
6. Mucin 1 and venous thrombosis in tumor-bearing mice and patients with cancer.
Kawano T; Englisch C; Hisada Y; Paul D; Archibald S; Grover S; Pabinger I; Ay C; Mackman N
Thromb Res; 2024 May; 237():23-30. PubMed ID: 38547690
[TBL] [Abstract][Full Text] [Related]
7. Organ-specific pancreatic tumor growth properties and tumor immunity.
Morikane K; Tempero RM; Sivinski CL; Nomoto M; Van Lith ML; Muto T; Hollingsworth MA
Cancer Immunol Immunother; 1999 Jan; 47(5):287-96. PubMed ID: 10022473
[TBL] [Abstract][Full Text] [Related]
8. Immunoregulation in pancreatic cancer patients.
Plate JM; Shott S; Harris JE
Cancer Immunol Immunother; 1999 Aug; 48(5):270-9. PubMed ID: 10478644
[TBL] [Abstract][Full Text] [Related]
9. Mucin-1-Antibody-Conjugated Mesoporous Silica Nanoparticles for Selective Breast Cancer Detection in a Mucin-1 Transgenic Murine Mouse Model.
Dréau D; Moore LJ; Alvarez-Berrios MP; Tarannum M; Mukherjee P; Vivero-Escoto JL
J Biomed Nanotechnol; 2016 Dec; 12(12):2172-2184. PubMed ID: 28522938
[TBL] [Abstract][Full Text] [Related]
10. A low-level expression of human MUC1 mucin enhances lethality of murine tumor cells.
Zimmermann GL; Krantz MJ; Kane KP; Longenecker BM
Cancer Immunol Immunother; 2000 Aug; 49(6):305-13. PubMed ID: 10946812
[TBL] [Abstract][Full Text] [Related]
11. A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis.
Jerome KR; Kirk AD; Pecher G; Ferguson WW; Finn OJ
Cancer Immunol Immunother; 1997 Jan; 43(6):355-60. PubMed ID: 9067407
[TBL] [Abstract][Full Text] [Related]
12. Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma.
Gautam SK; Batra SK; Jain M
Mol Cancer; 2023 Jul; 22(1):118. PubMed ID: 37488598
[TBL] [Abstract][Full Text] [Related]
13. The dark side of immunotherapy: pancreatic cancer.
Mucciolo G; Roux C; Scagliotti A; Brugiapaglia S; Novelli F; Cappello P
Cancer Drug Resist; 2020; 3(3):491-520. PubMed ID: 35582441
[TBL] [Abstract][Full Text] [Related]
14. Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma.
Dréau D; Moore LJ; Wu M; Roy LD; Dillion L; Porter T; Puri R; Momin N; Wittrup KD; Mukherjee P
Front Oncol; 2019; 9():330. PubMed ID: 31114758
[TBL] [Abstract][Full Text] [Related]
15. Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer.
Kajihara M; Takakura K; Kanai T; Ito Z; Matsumoto Y; Shimodaira S; Okamoto M; Ohkusa T; Koido S
World J Gastroenterol; 2016 May; 22(18):4446-58. PubMed ID: 27182156
[TBL] [Abstract][Full Text] [Related]
16. MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice.
Lakshminarayanan V; Supekar NT; Wei J; McCurry DB; Dueck AC; Kosiorek HE; Trivedi PP; Bradley JM; Madsen CS; Pathangey LB; Hoelzinger DB; Wolfert MA; Boons GJ; Cohen PA; Gendler SJ
PLoS One; 2016; 11(1):e0145920. PubMed ID: 26788922
[TBL] [Abstract][Full Text] [Related]
17. Genetically engineered mucin mouse models for inflammation and cancer.
Joshi S; Kumar S; Bafna S; Rachagani S; Wagner KU; Jain M; Batra SK
Cancer Metastasis Rev; 2015 Dec; 34(4):593-609. PubMed ID: 25634251
[TBL] [Abstract][Full Text] [Related]
18. Immune-maximizing (IMAX) therapy for cancer: Combination of dendritic cell vaccine and intensity-modulated radiation.
Shibamoto Y; Okamoto M; Kobayashi M; Ayakawa S; Iwata H; Sugie C; Mitsuishi Y; Takahashi H
Mol Clin Oncol; 2013 Jul; 1(4):649-654. PubMed ID: 24649223
[TBL] [Abstract][Full Text] [Related]
19. What is recent in pancreatic cancer immunotherapy?
Niccolai E; Prisco D; D'Elios MM; Amedei A
Biomed Res Int; 2013; 2013():492372. PubMed ID: 23509731
[TBL] [Abstract][Full Text] [Related]
20. Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine.
Laheru D; Biedrzycki B; Jaffee EM
Methods Mol Biol; 2013; 980():175-203. PubMed ID: 23359154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
